fluorine F 18 d-FMAU

RADIATION2 trials

Sponsors

Barbara Ann Karmanos Cancer Institute, University of Southern California

Conditions

Adenocarcinoma of the ProstateHormone-resistant Prostate CancerMalignant NeoplasmRecurrent Prostate CancerStage IV Prostate Cancer

Unknown Phase

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

CompletedNCT01812668

Barbara Ann Karmanos Cancer InstituteAdenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer +1

Start: 2013-03-31End: 2019-06-18Updated: 2021-08-05

18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

TerminatedNCT02079181

University of Southern CaliforniaMalignant Neoplasm

Start: 2014-01-31End: 2023-08-22Updated: 2024-05-24

Related Papers

The dynamics of biomarkers and bone imaging associated with oral cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2015-05-20